Overview

A Phase 2, Randomised Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic SCCHN

Status:
Recruiting

Trial end date:
2023-09-08

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the change in tumour size per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1) in recurrent or metastatic SCCHN patients treated with setanaxib and pembrolizumab versus patients treated with placebo and pembrolizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Genkyotex Suisse SA

Treatments:

Pembrolizumab